The barriers to entry are steep—the technology is patented
In the quiet machinery of global healthcare supply chains, a small Indian plastics manufacturer named Shaily Engineering finds itself at an unusual crossroads — where the expiry of a pharmaceutical patent, the rise of generic diabetes drugs, and the geometry of trade policy converge into what analysts at UBS believe is a rare, time-bound opportunity. Initiating coverage with a Buy rating and a price target of Rs 4,000 against a current price near Rs 2,547, UBS projects earnings growing at 75% annually through fiscal 2028, anchored by Shaily's early and entrenched position in the injector pen market for GLP-1 drugs. The story is one of patient preparation meeting a narrowing window — and the question, as always, is whether execution will honor the thesis.
- The 2026 expiry of semaglutide patents across India, Canada, and Brazil will unleash a wave of generic GLP-1 drugs — and Shaily has already secured supply relationships with 23 to 24 global pharma companies to deliver the injector pens they will need.
- UBS estimates the three-country injector pen market could reach Rs 80–85 billion annually by 2030, with Shaily positioned to capture 50–60% of it — a concentration of opportunity that makes the stock's trajectory unusually dependent on a single, high-stakes ramp.
- Existing consumer and industrial segments serving IKEA, Gillette, and GE Appliances have underperformed due to tariff disadvantages, but a potential India-US trade deal could unlock idle capacity and drive 18% revenue CAGR through FY28.
- The stock has already surged 137% from its 52-week low and nearly 700% over three years, meaning the market is pricing in optimism — but UBS argues another 60% remains on the table if execution holds.
- Veteran investor Ashish Kacholia holds over 5% of the company after more than a decade of ownership, while mutual funds and retail investors together own over 34%, signaling broad and deep conviction across the shareholder base.
UBS has initiated coverage of Shaily Engineering Plastics with a Buy rating and a price target of Rs 4,000 per share — a 60% premium to its current trading price of roughly Rs 2,547. The firm projects earnings per share will compound at 75% annually through fiscal 2028, a forecast rooted primarily in one carefully timed pharmaceutical opportunity.
The thesis centers on the 2026 patent expiry of semaglutide, the active ingredient in GLP-1 drugs used to treat diabetes and obesity. When generics enter the market across India, Canada, and Brazil, they will require hundreds of millions of injection devices. UBS estimates the combined market at 550–600 million units annually, worth Rs 80–85 billion by 2030. Shaily has already built relationships with 23 to 24 global pharma companies to supply those pens, giving it an estimated 50–60% share of the addressable market. The barriers protecting that position — patented technology, regulatory qualification hurdles, and high switching costs — make displacement difficult once a vendor is embedded.
Beyond healthcare, Shaily supplies precision plastic components to global names including IKEA, Gillette, Procter & Gamble, and Schaeffler. These segments have been constrained by unfavorable tariffs relative to competing emerging markets, but UBS expects a potential India-US trade agreement to change that calculus, projecting 18% revenue CAGR in consumer and industrial lines through FY28 as idle capacity is absorbed and margins expand.
The stock's journey has already been remarkable — up 137% from its 52-week low and roughly 700% over three years. Veteran Dalal Street investor Ashish Kacholia, who has held the stock for over a decade, owns 5.21% of the company, with shares now worth approximately Rs 610 crore. Mutual funds collectively hold nearly 12%, and more than 28,500 retail investors own a combined 23% stake.
UBS values the stock at 45 times the average of FY27 and FY28 estimated earnings. The entire thesis rests on execution: ramping GLP-1 production as generics launch, sustaining industrial customer relationships, and capturing the upside optionality of a new large customer in consumer electronics and semiconductors. The window is real — but it is also narrow, and the clock is already running.
UBS has begun covering Shaily Engineering Plastics, a maker of precision plastic components for healthcare, personal care, electronics, and industrial use. The stock, which trades at Rs 2,547.90, carries a buy rating and a price target of Rs 4,000—implying 60% upside from current levels. The firm projects earnings per share will grow at a 75% compound annual rate through fiscal 2028.
Shaily's appeal rests on a specific and narrowing window of opportunity. When the patent on semaglutide—the active ingredient in GLP-1 diabetes and weight-loss drugs—expires in 2026 across India, Canada, and Brazil, generic versions will flood the market. UBS estimates those three countries alone represent a market for 550 to 600 million injection devices, worth between Rs 80 and 85 billion in annual revenue by 2030. Shaily has already secured relationships with 23 to 24 global pharmaceutical companies to supply the injector pens for their generic versions. That arrangement gives the company an estimated 50 to 60 percent share of the addressable market in those geographies. The barriers to entry are steep—the technology is patented, regulatory approval is difficult to obtain, and switching costs are high for pharma companies once they've qualified a vendor.
Beyond the GLP-1 opportunity, UBS sees room for growth in Shaily's existing business serving consumer and industrial clients. The company supplies plastic components to IKEA, Gillette, Procter & Gamble, GE Appliances, and Schaeffler. Recent weakness in these segments has been tied to unfavorable tariff conditions relative to other emerging economies. UBS expects that a favorable trade agreement between India and the United States, with reduced tariffs, would unlock growth here. The firm forecasts an 18 percent revenue compound annual growth rate in these segments through fiscal 2028, with expanding margins and return on capital as the company utilizes idle capacity.
The stock has already moved substantially. From its 52-week low of Rs 1,073.90, it has climbed 137 percent. Over the past three years, it has surged roughly 700 percent. Year to date in 2025, it has gained nearly 75 percent. The company commands a market capitalization exceeding Rs 11,600 crore.
Ashish Kacholia, a veteran Dalal Street investor known for identifying multibagger opportunities, owns 5.21 percent of the company through himself and an affiliate entity, holding 23,93,680 shares worth approximately Rs 610 crore at current prices. He has held the stock for at least a decade. Mutual funds own 11.87 percent collectively, with Motilal Oswal Smallcap Funds holding 8.96 percent and Bandhan Smallcap Fund holding 1.70 percent. The Smallcap World Fund owns 5.48 percent. Retail investors—more than 28,500 of them—collectively own 22.97 percent of the company.
UBS's valuation assigns a 45 times price-to-earnings multiple to the average of fiscal 2027 and 2028 estimated earnings, arriving at the Rs 4,000 target. The thesis hinges on execution: Shaily must successfully ramp production for the GLP-1 injector pen market as generics launch, maintain its customer relationships in consumer and industrial segments, and benefit from tariff relief in a potential India-US trade agreement. The company is also in the process of winning a large customer in consumer electronics and semiconductors, which UBS views as providing additional upside optionality.
Notable Quotes
We believe the market is underestimating this opportunity and Shaily's capability.— UBS
Entry barriers are high due to patented technology and regulatory requirements, making it difficult for pharma companies to change injector vendors.— UBS
The Hearth Conversation Another angle on the story
Why does a plastic injection pen company warrant a 75% earnings growth forecast?
Because the market for GLP-1 generics is about to explode. When the patent expires in 2026, dozens of pharmaceutical companies will need injector pens. Shaily already has deals with 23 to 24 of them. That's not speculation—that's contracted revenue waiting to materialize.
But isn't the GLP-1 market already crowded? Why does Shaily have such a large share?
The technology is patented. You can't just copy an injector pen—it has to work reliably, pass regulatory approval, and integrate with the drug formulation. Once a pharma company qualifies Shaily's pen, switching to a competitor is expensive and risky. That's the moat.
The stock has already gone up 700% in three years. Isn't that a sign it's overvalued?
Not necessarily. The GLP-1 opportunity was always there, but the market may not have fully priced in the scale of it. A 550 to 600 million device market across three countries is enormous. And Shaily's existing business—supplying IKEA, P&G, GE—has been held back by tariffs. If those come down, that's a separate growth driver.
What could go wrong?
Execution risk is real. Shaily has to scale production without stumbling. A competitor could develop a non-infringing design. Or the India-US trade deal might not materialize. And if GLP-1 adoption slows, the entire thesis weakens.
Why is Ashish Kacholia still holding after 10 years?
Because he saw something the market underestimated. He's been right before. But that doesn't mean the stock can't fall. His conviction is a signal, not a guarantee.